GlaxoSmithKline’s new asthma drug gets a split vote from FDA advisers – FierceBiotech


Medscape

GlaxoSmithKline's new asthma drug gets a split vote from FDA advisers
FierceBiotech
GSK's injection, mepolizumab, works by blocking the protein interleukin-5 to prevent buildups of white blood cells in the lungs that can exacerbate asthma. The company is angling to get the drug approved as a treatment for sufferers of severe asthma
FDA Panel Backs Mepolizumab for Severe Eosinophilic AsthmaMedscape
GlaxoSmithKline plc (ADR) Wins FDA Panel Backing For Severe Asthma DrugBidness ETC
Asthma Drug Targeting IL-5 Wins Partial Backing From FDA AdvisersMedPage Today
Reuters –Nasdaq
all 32 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.